Literature DB >> 30178843

PCAT6 participates in the development of gastric cancer through endogenously competition with microRNA-30.

Y Xu1, J-Y Sun, Y-F Jin, H Yu.   

Abstract

OBJECTIVE: To investigate the role of lncRNA PCAT6 in the progression of gastric cancer and its underlying mechanism. PATIENTS AND METHODS: Expression levels of PCAT6 in 72 gastric cancer tissues and paracancerous tissues were detected by qRT-PCR (Quantitative Real-Time Polymerase Chain Reaction). The correlation between PCAT6 expression and clinical data of gastric cancer patients was analyzed by the chi-square test. After lentivirus transfection of PCAT6 in gastric cancer cells, proliferation, apoptosis, and invasion were detected by CCK-8 (cell counting kit-8), flow cytometry, and transwell assay, respectively. Western blot was utilized to detect protein expressions of apoptosis-related and EMT-related (epithelial-mesenchymal transition) genes in gastric cancer cells. Furthermore, target genes of PCAT6 were predicted via bioinformatics method and verified by luciferase reporter gene assay. The effects of target genes on biological functions of gastric cancer cells were determined as well.
RESULTS: PCAT6 was overexpressed in gastric cancer tissues than those of paracancerous tissues. PCAT6 expression was negatively correlated to prognosis, tumor size, TNM (tumor node metastasis) stage and metastasis of gastric cancer. For in vitro experiments, overexpression of PCAT6 increased proliferation, migration, and invasion, whereas decreased apoptosis of gastric cancer cells. MicroRNA-30 was predicted as the target gene of TCAT6. Furthermore, microRNA-30 was found to bind to TCAT6 via targeting MKRN3. Either microRNA-30 knockdown or PCAT6 overexpression could remarkably promote MKRN3 expression.
CONCLUSIONS: PCAT6 is overexpressed in gastric cancer, which promotes the development of gastric cancer by endogenously competition with microRNA-30 via targeting MKRN3.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178843     DOI: 10.26355/eurrev_201808_15718

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  13 in total

1.  LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.

Authors:  Yongjie Xin; Xu He; Wei Zhao; Meixiao Zhan; Yong Li; Jing Xiao; Ke He; Ligong Lu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

2.  Long-Noncoding RNA PCAT6 Aggravates Osteosarcoma Tumourigenesis via the MiR-143-3p/ZEB1 Axis.

Authors:  Kai Wu; Qiong Feng; Liang Li; Yanfei Xiong; Shihong Liu; Jie Liu; Qing Wu
Journal:  Onco Targets Ther       Date:  2020-08-26       Impact factor: 4.147

3.  Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer.

Authors:  Xuefei Shi; Zhili Liu; Zhicong Liu; Xueren Feng; Feng Hua; Xixian Hu; Bin Wang; Kaihua Lu; Fengqi Nie
Journal:  EBioMedicine       Date:  2018-10-09       Impact factor: 8.143

4.  LncRNA PCAT6 Accelerates the Progression and Chemoresistance of Cervical Cancer Through Up-Regulating ZEB1 by Sponging miR-543.

Authors:  Zhongping Ma; Guanghua Gu; Weikang Pan; Xiaoxiang Chen
Journal:  Onco Targets Ther       Date:  2020-02-07       Impact factor: 4.147

5.  Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3.

Authors:  Violeta Heras; Susana Sangiao-Alvarellos; Maria Manfredi-Lozano; María J Sanchez-Tapia; Francisco Ruiz-Pino; Juan Roa; Maribel Lara-Chica; Rosario Morrugares-Carmona; Nathalie Jouy; Ana P Abreu; Vincent Prevot; Denise Belsham; Maria J Vazquez; Marco A Calzado; Leonor Pinilla; Francisco Gaytan; Ana C Latronico; Ursula B Kaiser; Juan M Castellano; Manuel Tena-Sempere
Journal:  PLoS Biol       Date:  2019-11-07       Impact factor: 9.593

6.  The Cancer-Testis Long Non-coding RNA PCAT6 Facilitates the Malignant Phenotype of Ovarian Cancer by Sponging miR-143-3p.

Authors:  Xiaofang Tan; Yang Shao; Yue Teng; Siyu Liu; Weijian Li; Lu Xue; Yuepeng Cao; Chongqi Sun; Jinhong Zhang; Jing Han; Xiaoli Wu; Hanzi Xu; Kaipeng Xie
Journal:  Front Cell Dev Biol       Date:  2021-02-04

Review 7.  PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis.

Authors:  Song-Bo Shi; Qing-Hao Cheng; Shi-Yi Gong; Ting-Ting Lu; Shi-Fang Guo; Shao-Ming Song; Yu-Ping Yang; Qi Cui; Ke-Hu Yang; Yao-Wen Qian
Journal:  Cancer Cell Int       Date:  2021-07-12       Impact factor: 5.722

8.  Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis.

Authors:  Bo Liu; Hui-Yang Jiang; Tao Yuan; Jie Luo; Wei-Dong Zhou; Qi-Quan Jiang; Denglong Wu
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244

Review 9.  The Role of lncRNA PCAT6 in Cancers.

Authors:  Siying Wang; Zhenyao Chen; Jingyao Gu; Xin Chen; Zhaoxia Wang
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

10.  Knockdown of lncRNA PCAT6 Enhances Radiosensitivity in Triple-Negative Breast Cancer Cells by Regulating miR-185-5p/TPD52 Axis.

Authors:  Rui Shi; Peng Wu; Miaomiao Liu; Bing Chen; Longjiao Cong
Journal:  Onco Targets Ther       Date:  2020-04-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.